treatment of drug use

Displaying 1 - 20 of 197

cover of report Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons

Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons

Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live, with European countries having to introduce unprecedented measures to protect public health. As with all areas of life, drug consumption, related harms and drug markets have been impacted, as have the services...

image of covid19 virus

EMCDDA releases third trendspotter study on COVID-19 and drugs

The EMCDDA releases today the third in a series of rapid ‘trendspotter’ studies exploring the impact of COVID-19 on the drug situation and responses to it. Revisiting and reviewing findings from two studies in 2020 on the effects of the pandemic on drug use and services, the report identifies new...

medicine cup with green methadone

Maximising access to drug treatment while minimising diversion of medications — new EMCDDA report looks at striking the balance

Opioid substitution treatment (OST) is a key evidence-based tool used to manage opioid dependence and improve related health and social consequences. Yet increasing reports of the diversion and misuse of the controlled drugs used in this treatment in Europe are a cause for concern. In a new report...

Events

Launch of report: Balancing access to OST with preventing the diversion of opioid substitution medications in Europe: challenges and implications

Read about the report in the news section. Read the full report here >>

cover of publiatoin title reads: balancing access to opioid substitution treatment with preventing the diversion of opioid substitution medications in Europe: challenges and implications

Balancing access to opioid substitution treatment (OST) with preventing the diversion of opioid substitution medications in Europe: challenges and implications

This report reviews how opioid substitution treatment (OST) is implemented in European countries and examines the public health consequences of the diversion and misuse of prescription OST medications. It looks at how OST medications are diverted to the illicit market, the motivations behind...

Document library

Document library

Impact of the COVID-19 epidemic on drug markets, substance use patterns, and delivery of harm reduction and treatment services in Ukraine

This mixed-methods study was conducted to monitor the trends in the drug scene, substance use practices, and availability of prevention and treatment services for people who use drugs in Ukraine in...

Document library

Document library

The double effect of COVID-19 confinement measures and economic recession on high-risk drug users and drug services

The ongoing COVID-19 pandemic is likely to have a profound impact on the lives of high-risk drug users and on the services responding to their needs in at least two important ways: first, through the...

EMCDDA Best practice portal update (4/2020)

Evidence updates on social reintegration and employment-focused interventions Employment is one of the strongest predictors of positive outcomes for persons with substance use disorder. Unemployed clients in treatment often report that their current unemployment is due to substance use. They also...

Events

Minimal drug-treatment data set: coordination and data collection in Western Balkan countries

The EMCCDA is in the process of launching a project to establish a routine data collection on drug treatment. The project aims to assist national experts and national drug observatories/national...

open door

EMCDDA Best practice portal update (3/2020)

Substitution treatment for stimulants users? Finding a pharmacological treatment for stimulant users has been a research priority for the last decade. Many classes of drugs have been tested: antidepressants, dopamine agonists, antipsychotics, anticonvulsants, disulfiram, opioid agonists, N-...

Screenshot of EDR 2020 video

Video: 2020 European Drug Report: Key Issues

High availability across all drug types, drug production within Europe and highly potent substances are among the concerns addressed today by the (EMCDDA in its European Drug Report 2020: Trends and Developments. In its latest annual review — marking 25 years of monitoring — the agency describes...

publication cover

European Drug Report 2020: Key Issues

This report, available in 24 languages, presents a summary of some the main findings of the 'European Drug Report 2020: Trends and Developments the EMCDDA’s latest analysis of the drug situation in Europe. The issues selected here have been chosen for their policy relevance and general interest.

Data

Statistical Bulletin 2020 — treatment demand data

European Drug Report 2020: Trends and Developments

This report provides a comprehensive analysis of patterns emerging across Europe in the areas of drug supply, illicit drug use and associated public health problems. National data sets are also provided across these themes and on key harm-reduction interventions. The report is available in English...

Document library

Document library

COVID-19, drug consumption and addiction in Spain

The COVID 19 epidemic has had a major impact on people's daily lives and is an unprecedented challenge for health services that care for people with addiction. In order to know the potential impact...

Publication cover

EMCDDA Trendspotter briefing: impact of COVID-19 on patterns of drug use and drug-related harms in Europe

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people who use drugs in Europe, the EMCDDA instigated a mixed-...

screenshot of page

COVID-19 resource page for people who use drugs (PWUD) and drug service providers

On this page, the EMCDDA has compiled examples of advice being issued to people who use drugs and service providers by some national bodies and different associations, networks and NGOs. This resource is online only and may be accessed here >>

EMCDDA trendspotter briefing - Impact of COVID-19 on drug services and help-seeking in Europe

Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug services in Europe, the European Monitoring Centre for...

Computer-generated simulation of a corona virus (copyrighted)

EMCDDA publishes update on the implications of COVID-19 for people who use drugs and for drug service providers

What specific risks are people who use drugs (PWUD) likely to face during the COVID-19 pandemic? What services will they need? How will professionals working with this group need to adapt on the frontline? These are among the questions raised in a new EMCDDA update published today. The update is...

Document library

Document library

Opioid agonist therapy (OAT) and the COVID-19 pandemic: recommendations of the SSAM (Switzerland)

The Swiss Addiction Medicine association provides recommendations to doctors and services providing OST during the pandemic to ensure continuity of services.

1
2
3
4
5
6
7
8
9
next ›

.

Loading